Drug intelligence / Profile preview

biotinylcholesterylformylhydrazide

Development stage: Unknown
Modality: Small Molecules

Overview

Biotinylcholesterylformylhydrazide (MSB1) is a novel lipophilic cholesteryl-based biotin derivative. It functions as a key component within cationic liposomes, which are part of transfecting assemblies known as lipoplexes. MSB1 provides docking points for tribiotinylated transferrin-streptavidin accessories on these liposomes, facilitating the targeted delivery of plasmid DNA into cells, such as human cervical carcinoma (HeLa) cells, through receptor-mediated endocytosis.

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on biotinylcholesterylformylhydrazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on biotinylcholesterylformylhydrazide.

Explore the full profile